Amgen Inc. (NASDAQ:AMGN) Plans $2.52 Quarterly Dividend

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Thursday, July 30th. Investors of record on Friday, August 21st will be paid a dividend of 2.52 per share by the medical research company on Friday, September 11th. This represents a c) dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st.

Amgen has increased its dividend by an average of 0.1%per year over the last three years and has raised its dividend every year for the last 14 years. Amgen has a payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $23.86 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 42.2%.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $387.64 on Friday. Amgen has a 1-year low of $269.77 and a 1-year high of $398.00. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a market cap of $209.21 billion, a P/E ratio of 26.98, a P/E/G ratio of 3.92 and a beta of 0.41. The firm has a fifty day moving average price of $355.69 and a 200 day moving average price of $353.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.90 earnings per share. Sell-side analysts predict that Amgen will post 22.31 EPS for the current year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp grew its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the period. Capital World Investors increased its holdings in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC increased its holdings in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $2,164,162,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.